Brand vs generic: the battle rages over EU anti-counterfeit 'safety features'
This article was originally published in SRA
Executive Summary
The positions of originator and generics companies on the future "safety feature" on EU product packs are as far apart as ever, with the former still insisting that all prescription drugs should in principle have to carry the feature and the generics industry claiming a general exemption for their products on both risk and cost grounds1,2.